

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12444A	Serial No 09/998,393
	Applicants Charles Jack Fisher, et al.	
	Filing Date 11-2-2001	Group 1654

 1654 U.S. PTO
09/998393

11/02/01

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
JR	AA	5,453,373	09/26/95	Gerlitz, et al.	435	240.2	07/09/93
JR	AB	5,516,650	5/14/96	Foster, et al.	435	68.1	04/08/94
JR	AC	4,981,952	01/01/91	Yan	530	384	08/16/89
JR	AD	5,478,558	12/26/95	Bibl, et al.	424	94.63	04/28/95
JR	AE	5,198,541	03/30/93	Elisbach, et al.	435	69.1	12/11/91
JR	AF	5,550,036	08/27/96	Grinnell	435	69.1	03/09/94
JR	AG	5,733,872	03/31/98	Little	514	12	03/11/94
JR	AH	5,627,262	05/06/97	Pereira	530	324	06/07/95
JR	AI	5,753,620	05/19/98	Friedmann, et al.	514	12	01/24/95
JR	AJ	5,607,916	03/04/97	Pereira, et al.	514	12	04/29/94
JR	AK	5,756,464	05/26/98	Scannon, et al.	514	12	09/10/97
JR	AL	5,308,834	05/03/94	Scott, et al.	514	12	12/14/92
JR	AM	4,775,624	10/04/88	Bang, et al.	435	226	02/08/85
JR	AN	4,992,373	02/12/91	Bang, et al.	435	226	12/04/87
JR	AO	5,171,739	12/15/92	Scott, et al.	514	12	04/05/91

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
JR	BA	WO 97/20043	6-5-1997	WO/PCT				
JR	BB	EP 0 445 939	9-11-1991	Europe				
	BC							

EXAMINER Jeffrey E. Russell	DATE CONSIDERED March 17, 2003
--------------------------------	-----------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-12444A	Serial No 09/988593
		Applicant Charles Jack Fisher, et al.	
		Filing Date 11-2-2001	Group 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JR	CA	Elsbach, "Separation and Purification of a Potent Bactericidal/Permeability-Increasing Protein and a Closely Associated Phospholipase A ₂ form Rabbit Polymorphonuclear Leukocytes", <u>J. Biol. Chem.</u> 254:11000, 1979.	
JR	CB	Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", <u>Blood</u> 69:652, 1987.	
JR	CC	Mesters, et al., "Factor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patients", <u>Blood</u> 88:881-886, 1996	
JR	CD	Fourrier, et al., "Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation", <u>Chest</u> 101:816-823, 1992.	
JR	CE	Natanson, et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", <u>Ann. Intern. Med</u> 120:771-783, 1994	
JR	CF	Gibaldi, "Anatomy of an Antibody, and Related Misadventures in Developing an Effective Treatment for Septic Shock", <u>Pharmacotherapy</u> 13(4):302-308, 1993.	
JR	CG	Parrillo, "Pathogenetic Mechanisms of Septic Shock", <u>N. Engl. J. Med.</u> 328(20):1471-1477, 1993.	
JR	CH	Taylor, et al., "Protein C Prevents the Coagulopathic and Lethal Effects of <i>Escherichia coli</i> Infusion in the Baboon", [<u>J. Clin. Invest.</u> 79:918-25, 1987.	
JR	CI	Gerson, et al., "Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate", <u>Pediatrics</u> 91(2):418-422, 1993.	
JR	CJ	Smith, et al., "Successful Treatment of Meningococcal Induced Protein C Deficiency/Purpura Fulminans in Children with Protein C Concentrate and Heparin", <u>Thromb. Haemost.</u> 78:1709, p419, 1997.	
JR	CK	Rintala, et al., "Protein C in the Treatment of Coagulopathy in Meningococcal Disease", <u>Lancet</u> 347:1767, 1996.	
JR	CL	Rivard, et al., "Treatment of Purpura Fulminans in Meningococcemia with Protein C Concentrate", <u>J. Pediatr.</u> 126:646-652, 1995.	
JR	CM	Fisher, et al., "Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study", <u>Crit. Care Med.</u> , 22(4): 553-558, 1994.	
JR	CN	Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", <u>J. Biol. Chem</u> 264(16):9505, 1989.	
JR	CO	Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils", <u>J. Exp. Med.</u> 174:649, 1991.	
JR	CP	Gazzano-Santoro et al., "High-Affinity Binding of a Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", <u>Infect. Immun.</u> 60(11):4754-4761, 1992.	
JR	CQ	Grinnell, et al., "Trans-Activated Expression of Fully Gamma-Carboxylated Recombinant Human Protein C, An Antithrombotic Factor", <u>Bio/Technology</u> 5:1189-1192, 1987.	
JR	CR	McGrogan, et al, "Molecular Cloning and Expression of Two Forms of Human Protease Nexin I". <u>Biotechnology</u> , 6: 172-177(2-1988)	
EXAMINER		DATE CONSIDERED	
Tepfer, E. Russell		March 17, 2003	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPBP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

U.S. PRO
09/988593
11/02/01

